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PRECLINICAL RESEARCH
cute and Chronic Reduction of
unctional Mitral Regurgitation in Experimental
eart Failure by Percutaneous Mitral Annuloplasty
alin V. Maniu, MD,* Jeetendra B. Patel, MD,* David G. Reuter, MD, PHD,† Donna M. Meyer,*
illiam D. Edwards, MD,‡ Charanjit S. Rihal, MD,* Margaret M. Redfield, MD*
ochester, Minnesota; and Kirkland, Washington
OBJECTIVES We sought to determine acute and chronic efficacy of a percutaneous mitral annuloplasty
(PMA) device in experimental heart failure (HF). Further, we evaluated the potential for
adverse effects on left ventricular (LV) function and coronary perfusion.
BACKGROUND Reduction of mitral annular dimension with a PMA device in the coronary sinus may reduce
functional mitral regurgitation (MR) in advanced HF.
METHODS Study 1: a PMA device was placed acutely in anesthetized open-chest dogs with rapid
pacing-induced HF (n  6) instrumented for pressure volume analysis. Study 2: in 12
anesthetized dogs with HF, fluoroscopic-guided PMA was performed, and dogs were
followed for four weeks with continuing rapid pacing.
RESULTS Study 1: percutaneous mitral annuloplasty reduced annular dimension and severity of MR at
baseline and with phenylephrine infusion to increase afterload (MR jet/left atrial [LA] area
26  1% to 7  2%, p  0.05). Pressure volume analysis demonstrated no acute impairment
of LV function. Study 2: no device was placed in two dogs because of prototype size
limitations. Attempted PMA impaired coronary flow in three dogs. Percutaneous mitral
annuloplasty (n 7) acutely reduced MR (MR jet/LA area 43 4% to 8 5%, p 0.0001),
regurgitant volume (14.7 2.1 ml to 3.1 0.5 ml, p 0.05), effective regurgitant orifice area
(0.130  0.010 cm2 to 0.040  0.003 cm2, p  0.05), and angiographic MR grade (2.8 
0.3 device to 1.0  0.3 device, p  0.001). In the conscious state, MR was reduced at four
weeks after PMA (MR jet/LA area 33 3% HF baseline vs. 11 4% four weeks after device,
p  0.05)
CONCLUSIONS Percutaneous mitral annuloplasty results in acute and chronic reduction of functional MR in
experimental HF. (J Am Coll Cardiol 2004;44:1652–61) © 2004 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.03.085of Cardiology Foundation
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catients with dilated cardiomyopathy due to ischemia or
rimary myocardial disease develop secondary “functional”
itral regurgitation (MR). The putative mechanisms are
nlargement of the mitral annulus caused by ventricular and
trial dilation, dysfunction of the papillary muscles second-
See page 1662
ry to conformational changes of the enlarged left ventricle
LV), and disturbances in the normal contraction sequence
f the different myocardial segments (1). Chronic volume
verload associated with MR in the failing heart can
xacerbate the hemodynamic strain on the failing LV,
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Manuscript received November 21, 2003; revised manuscript received March 2,
004, accepted March 25, 2004.ontributing to further LV remodeling, worsening symp-
oms, and reduced survival.
Surgical repair of the mitral valve via placement of an
nnuloplasty ring has been demonstrated to improve symp-
oms, and possibly survival, in patients with severe LV
ysfunction and advanced heart failure (HF) (2). However,
idespread use of surgical mitral annuloplasty as a “stand-
lone” therapy for advanced HF has been limited because of
oncern regarding the significant morbidity and mortality
ssociated with surgical procedures in this patient
opulation.
The coronary sinus (CS) follows a circumferential course
n the atrial side of the atrioventricular groove at a distance
f 10 to 14 mm along the posterolateral aspect of the mitral
nnulus (3). The relationship of the CS to the mitral
nnulus has led investigators to develop CS devices that can
educe mitral annular dimension and offer the potential for
ercutaneous mitral annuloplasty (PMA). If effective, PMA
ay offer the hemodynamic benefit of reduction of MR
ithout the inherent risks of cardiac surgery in patients with
dvanced HF. In the 15% of patients with a left dominant
oronary circulation, the circumflex coronary artery (CX)
arallels the entire length of the posterior leaflet. In patients
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October 19, 2004:1652–61 Percutaneous Mitral Annuloplastyith a right dominant coronary circulation, the intimate
elationship of the CX to the CS is most pronounced in the
istal CS, near the anterior commissure of the mitral valve.
he CX crosses superior to the CS in 33% of cases and
etween the CS and the annulus in the remaining 67% of
ases (4,5). Thus, compression of the circumflex with the
ension applied via the CS is a potential concern. The
bjectives of this study were to determine if placement of a
ovel annuloplasty device (Fig. 1) in the CS would result in
cute and chronic reduction in the severity of functional MR
ssociated with chronic experimental HF in dogs. Further,
e sought to determine if adverse effects on LV function or
oronary flow were associated with device placement.
ETHODS
wo studies were performed. In the first study, dogs with
xperimental HF produced by rapid ventricular pacing were
nesthetized, underwent sternotomy, and were instru-
ented for pressure volume (sonomicrometry crystals) anal-
sis and epicardial echocardiography. The acute effects of
MA on annular dimension, MR severity, and hemody-
amics were assessed at baseline and during after-load
ncreases produced by phenylephrine. In the second study,
ogs with experimental HF underwent conscious echocar-
iography to assess MR severity and LV function and then
nderwent PMA under fluoroscopic guidance with assess-
ent of coronary flow, mitral regurgitation severity (con-
Abbreviations and Acronyms
CS  coronary sinus
CX  left circumflex coronary artery
ERO  effective regurgitant orifice
HF  heart failure
LA  left atrium/atrial
LV  left ventricle/ventricular
MR  mitral regurgitation
PISA  proximal isovelocity surface area
PMA  percutaneous mitral annuloplasty
igure 1. Illustration of the annuloplasty device. The distal and proximal
nchors are collapsed before insertion and the device is delivered to the
oronary sinus (CS) via a guide catheter. The distal anchor is deployed in
he distal coronary sinus and locked. Tension is then applied via the
elivery system until satisfactory acute efficacy with stable coronary perfu-w
ion is documented. The proximal anchor is then deployed and locked in
he proximal CS. The delivery system is then uncoupled and removed.rast ventriculography and transthoracic Doppler echocar-
iography), and hemodynamics before and after PMA.
ogs were then followed during continued rapid pacing
ith repeat conscious echocardiography at four weeks after
MA to assess chronic efficacy. Pathologic assessment of
oronary anatomy was performed in explanted hearts. The
ayo Institutional Animal Care and Use Committee ap-
roved all experimental procedures.
tudy 1. Experiments were performed in six male mongrel
ogs (20 to 28 kg).
XPERIMENTAL HF WITH FUNCTIONAL MR. We utilized a
odification of the rapid pacing model of cardiomyopathy
6). Dogs were anesthetized with ketamine (10 mg/kg),
iazepam (0.5 mg/kg), and isoflurane (0.5% to 2.5%). Via a
eft thoracotomy, a pacing lead was placed on the right
entricle. After two weeks, the pacemaker was programmed
t progressively higher rates: 180 beats/min for two weeks,
00 beats/min for one week, 210 beats/min for one week,
20 beats/min for one week, and 240 beats/min for one
eek.
CUTE EXPERIMENTAL PROTOCOL. The pacemaker was
urned off and animals were anesthetized with fentanyl (0.25
g/kg) and midazolam (0.75 mg/kg) followed by infusion
f fentanyl (0.18 mg/kg/h) and midazolam (0.59 mg/kg/h),
ntubated, and ventilated. Via a sternotomy, ultrasonic
rystals (Sonometrics Corporation, London, Canada) were
laced on the endocardial surface and intramyocardially in
he long and short axis of the LV through stab wounds.
icromanometer-tipped catheters (Millar Instruments,
ouston, Texas) were placed in the LV via the right femoral
rtery and in the left atrium (LA) via the LA appendage and
alibrated. Hemodynamic data and epicardial echocardio-
raphic images were obtained immediately before and after
lacement of the annuloplasty device under basal conditions
nd during intravenous infusion of phenylephrine to in-
rease afterload.
LACEMENT OF THE ANNULOPLASTY DEVICE. A guide cath-
ter was positioned in the CS through the right external jugular
ein. The device was advanced up to the turning point of the
reat cardiac vein (referred to as the distal CS henceforth) into
he anterior interventricular groove. The distal anchor of the
evice was deployed and traction was applied on the proximal
nd, simulating the conformational change induced by deploy-
ent of the proximal anchor (i.e., the device was cinched).
fter data collection, the traction was released and a phenyl-
phrine continuous infusion (10-g/min and increasing by
0-g/min increments to achieve increases in systolic LV
ressure of 30 mm Hg) was started. Intravenous atropine was
dministered if bradycardia occurred. Once the target pressure
as achieved, collection of hemodynamic and echocardio-
raphic data was repeated before and after applying traction on
he proximal end of the device (device cinching).
EMODYNAMIC ANALYSIS. Pressure and dimension signals
ere acquired and analyzed with CardioSoft (Sonometrics
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Percutaneous Mitral Annuloplasty October 19, 2004:1652–61orp., London, Ontario, Canada) as previously reported to
ield LV volumes and parameters of systolic and diastolic
unction (7).
CHOCARDIOGRAPHIC ANALYSIS. Epicardial two-
imensional and color flow images were obtained and
nalyzed off-line with a commercially available console and
nalysis system (Vingmed System Five and EchoPAC, GE
edical Systems, Milwaukee, Wisconsin). Para-apical im-
ges were analyzed. The largest diastolic diameter of the
itral annulus, the largest MR jet area, and the correspond-
ng LA area were measured. The severity of MR was
ssessed by the MR jet area/LA area ratio (8).
tudy 2. Experiments were performed in 12 mongrel dogs
20 to 30 kg). The study was performed in three phases that
ncluded slightly different prototypes of the device (Phase 1
prototype 1, n  4], Phase 2 [n  2, prototype 2], and
hase 3 [n  6, prototype 3]).
TUDY PROTOCOL. Heart failure was induced by the mod-
fied pacing protocol described earlier and all dogs had an
dditional week of pacing at 200 beats/min before device
lacement. Echocardiography was performed on each dog
efore initiation of pacing and at the end of pacing protocol.
able 1. Effect of Annuloplasty Device on Hemodynamics and M
Baseline
eak LV pressure (mm Hg) 87.3  4.9
V minimum pressure (mm Hg) 4  0.8
V end-diastolic pressure (mm Hg) 11.3  2.5
ean LA pressure (mm Hg) 8.7  1.4
dP/dt (mm Hg/s) 933 94
au (ms) 64  15
V end-diastolic volume (ml) 91.8  10.1
V ejection fraction (%) 24  5
V stroke volume (ml) 20.8  4.1
eart rate (beats/min) 95  10
ardiac output (l/min) 1.8  0.3
itral annulus diameter (cm)¶ 2.7  0.2
R jet area (cm2) 2.2  0.7
R jet/LA area (%) 16  4
p  0.05 versus baseline, †p  0.052 versus baseline, ‡p  0.05 versus baseline, §p
0.1 cm.
LA  left atrial; LV  left ventricular; MR  mitral regurgitation.
able 2. Cardiac Structure and Function and Severity of MR at
evice Implantation Procedure in Dogs That Did (n  7) or Di
Echocardiographic
Parameter
LVEDD
(cm)
Left Atria
Area
(cm2)
evice implanted (n  7)
Baseline 4.29 0.08 16.3 0.7
HF pre-device 5.11 0.20* 26.1 1.0
HF  device  4 weeks 5.31 0.19 25.4 2.0
o device implanted (n  3)
Baseline 4.30 0.20 19.8 1.5
HF pre-device 5.38 0.32* 26.2 2.2
HF  4 weeks 5.49  0.17 31.0 4.0p  0.05 HF predevice vs. baseline; †p  0.05 HF  device  4 weeks vs. HF-predevic
HF  heart failure; LVEDD  left ventricular end-diastolic dimension; LA  left atrnimals were taken to the catheterization laboratory where
mplantation of the device was performed under anesthesia
nd its efficacy measured with the pacemaker off (sinus
hythm). After device placement, the animals were allowed
o recover for three days and then pacing was resumed at
00 beats/min. Transthoracic echocardiography was per-
ormed after four weeks and animals were sacrificed.
LACEMENT OF DEVICE. Anesthesia was induced by ket-
mine (10 mg/kg) or diazepam (0.5 mg/kg) and was
aintained with isoflurane (0.5% to 2.5%). The left femoral
rtery and right jugular vein were surgically isolated and
annulated with a 9F sheath. Left ventricular pressure was
easured at baseline and after device placement. Contrast
entriculography was performed at baseline and after device
lacement. Transthoracic echocardiography was performed
nd mitral annular dimension and MR severity (MR jet
rea/LA area) were assessed as described earlier. Proximal
sovelocity surface area (PISA) measurements were made at
aseline and after device therapy. The jet area was also
ssessed intermittently during device placement to assess
fficacy with variations in placement of the device. Under
uoroscopic guidance, the CS was cannulated with a flexible
the Absence and Presence of Phenylephrine
Device Phenylephrine
Phenylephrine
 Device
88.3  6.2 117.7 10.6‡ 118.6  11.2
3.2  1.2 7.6  2.0 8.2  3.5
10.1  2.7 19.3 2.7‡ 19.2  3.3
8.2  1.1 12.1  1.0 11.6  1.8
845  153 1,385  194‡ 1,368  187
57  8 98  28 100  27
88.8  11.9 100.9 9.6‡ 100.5  9.8
26  6 27  5 25  4§
22.3  6 27.1  6.4 24.3  6.2§
84  9 89  11 90  11
1.7  0.4 2.2  0.4 2.0  0.4§
2.3  0.1* 2.7 0.1 2.3  0.1§
0.5  0.2* 3.3 0.5 0.8  0.2§
4  1† 26  1‡ 7  2§
5 versus phenylephrine. ¶The mitral annulus diameter in normal dogs (n  8) is 2
ine, After Induction of Heart Failure, and 4 Weeks After
t (n  3) Receive a Mitral Annuloplasty Device
Ejection
Fraction
(%) MR Jet Area/LA Area
Mitral
Annulus
(cm)
68 2 0.00 3.17  0.08
33 3* 0.33  0.03* 3.75 0.08*
30 3 0.11  0.04†‡ 3.37  0.23‡
69 1 0.00 2.82  0.28
33 4* 0.40  0.02* 3.50 0.11*
28 6 0.39  0.05 3.73 0.11R in
 0.0Basel
d No
l
*
*e; ‡p  0.05 HF  device  4 weeks vs. HF  4 weeks.
ial; MR  mitral regurgitation.
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October 19, 2004:1652–61 Percutaneous Mitral Annuloplastyuide catheter. A CS venogram was performed to measure
he length and width of CS, particularly at the sites that
ould interface with the proximal and distal device anchors.
he CS venogram was repeated after device placement to
xclude dissection/disruption of the CS. A measuring cath-
ter was also introduced into CS to assist in device sizing.
oronary angiography was performed at baseline, intermit-
ently during positioning of the device, and again after final
lacement.
The mitral annuloplasty device was selected after baseline
easurements of the size of CS. With experience, use of
arking catheters improved assessment of CS size in the HF
ogs, and the range of device sizes needed on hand was more
redictable. The device was advanced into the CS and the
istal end was deployed at variable percentages (75% to 95%)
f the distance between the CS and the anterior intraventric-
lar vein. Transthoracic echocardiography was performed
hile putting tension at the distal end and pulling it in
ncrements of 1 cm each (“cinching the device”). If traction
igure 2. Effect of annuloplasty device on annular dimension and mitral reg
a,b) or presence (c,d) of phenylephrine (PE) infusion. Arrows  MR jetailed to reduce MR jet area/LA area by50%, the device was aecaptured and a new device was placed with the distal anchor
ositioned further out in the CS and traction was reapplied
ssessing MR severity and coronary flow. If the MR was
educed by 50% and coronary flow was preserved, the
roximal anchor was deployed and the device was uncoupled
rom the delivery system. After full device deployment, final
ssessments of MR severity (Doppler echocardiography and
ontrast ventriculography), coronary flow, CS venogram, and
V hemodynamics were performed. If LV systolic pressures
ere lower at the final MR assessment, phenylephrine was
nfused at a dose titrated to provide similar LV systolic
ressures at the baseline and final studies. This was necessary in
nly one dog.
CHOCARDIOGRAPHY. Transthoracic two-dimensional and
olor flow images were obtained as noted for Study 1.
dditionally, during the placement of the device, the MR
everity was assessed by the PISA method with calculation
f the regurgitant volume and effective regurgitant orifice
tion (MR) in Study 1. Epicardial echocardiographic images in the absence
 left atrium; LV  left ventricle.urgitarea (ERO). This assessment requires measurement of the
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Percutaneous Mitral Annuloplasty October 19, 2004:1652–61adius (cm) of the PISA in the LV, the aliasing velocity, and
he velocity and time-velocity integral of the continuous-
ave MR signal. The ERO and the regurgitant volume
ere then calculated using the standard formulas (9). As
ogs are considerably smaller than humans, with smaller
earts and lower cardiac output, no criteria exist regarding
he relationship of PISA values to severity of MR.
For echocardiographic measurements in conscious dogs,
nly the parasternal short- and long-axis views were possible
ith the dog standing, thus PISA assessment of MR was
ot possible. Two-dimensional guided M-mode measure-
ents of LV end-diastolic and end-systolic dimension were
ade in the short-axis view and ejection fraction was
alculated using the Teichholz formula. Two-dimensional
easurements of the transverse annular dimension in the
hort-axis view and the long-axis view were made. The
aximal MR jet area in the long-axis view and correspond-
ng LA area were measured.
ONTRAST VENTRICULOGRAPHY. Mitral regurgitation se-
erity was graded (0 to 4) using criteria similar to those used
n humans. As blinding of the interpreter as to the presence
r absence of the device was not possible, the interpreter
raded the MR in the pre- and post-device ventriculograms
n separate batches blinded to the identity of the dog and
he previous or subsequent ventriculogram.
ATHOLOGY. Nine of the 12 hearts were available for
athologic examination with perfusion fixation in most.
igure 3. Effect of annuloplasty device on left ventricular (LV) volumes a
nd after (red) cinching of the device and the corresponding LV and left atri
racings before and after cinching of the device during phenylephrine (PEearts were sectioned and analyzed with an experienced tardiac pathologist (W.D.E.) paying particular attention to
he relationship of the CS, circumflex coronary artery, and
itral annulus in the area of the distal CS, proximal
ircumflex, and distal anchor.
TATISTICAL ANALYSIS. Data were averaged and reported
s mean  SEM. Paired and unpaired t tests were used for
tatistical comparisons. A probability value of p  0.05 was
onsidered significant.
ESULTS
tudy 1. PACING-INDUCED HF. The rapid pacing protocol
esulted in LV dilation and severe systolic and diastolic
ysfunction (Tables 1 and 2).
CUTE EFFECT OF PERCUTANEOUS ANNULOPLASTY ON THE
EGREE OF MR AND HEMODYNAMICS IN THE ABSENCE AND
RESENCE OF PHENYLEPHRINE. Cinching the device re-
ulted in a decrease in the mitral annulus diameter, the MR
et area, and the MR jet area/LA area ratio (Table 1, Fig. 2).
here were no significant changes in LV pressures, volumes,
nd systolic or diastolic function (Table 1, Fig. 3). The LA
ressure did not increase. Compared with the baseline state,
henylephrine infusion resulted in increases in peak LV
ystolic pressure, end-diastolic pressure, end-diastolic vol-
me, positive dP/dt, and MR jet area/LA area ratio (Table
, Figs. 2 and 3). There were no significant changes in the
ther parameters. During phenylephrine infusion, cinching
modynamics. Above are shown LV pressure-volume loops before (black)
) pressures. Below are LV pressure-volume loops and LV and LA pressure
sion. ECG  electrocardiogram.nd he
al (LA
) infuhe device resulted in small but statistically significant
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October 19, 2004:1652–61 Percutaneous Mitral Annuloplastyecreases in LV stroke volume and ejection fraction while
he mitral annulus diameter, MR jet area, and the MR jet
rea/LA area ratio decreased dramatically. The methodol-
gy we employed for calculating stroke volume (end-
iastolic minus end-systolic volume) includes “forward”
effective) and regurgitant volume; therefore, the small
ecrease in stroke volume could be related to the observed
ecrease in MR.
tudy 2. PLACEMENT OF THE DEVICE IN DOGS WITH EX-
ERIMENTAL HF. Four dogs were studied in phase 1 with
he first prototype of the device. The anchors of this
rototype were undersized; in two dogs, the device could
ot be placed as the anchors were too small to stabilize the
evice. In one dog, a suitable size was available and the acute
nd chronic effects were assessed. In the fourth dog, a
uitable size was available, an acute effect was demonstrated,
nd the device was deployed. While preparing to perform
igure 4. Variable proximal circumflex coronary artery (CX) and distal cor
oronary angiography demonstrating intact CX anatomy after device (D). S
rtery; MV  mitral valve; P Anc  proximal anchor; other abbreviationoronary angiography after final device placement, the dog abrillated presumably due to impingement on coronary flow
ut resuscitation was unsuccessful and documentation of
ircumflex occlusion was not possible. After this experi-
ent, the protocol was altered to mandate repeated angiog-
aphy during the positioning of the device, not just after
nal placement. Two dogs were studied in phase 2 (proto-
ype 2) with successful device placement. Six dogs were
tudied in phase 3 (prototype 3) with device placement in
our dogs and inability to implant a device due to coronary
mpingement in two (fatal in 1).
In 7 of the 12 dogs, the distal anchor was able to be
eployed distally (at 75% to 95% of distance between CS os
nd anterior intraventricular vein) in the CS with acute
fficacy and no impingement of coronary flow (Fig. 4D).
hree patterns of the course of the CX and CS were noted.
n four dogs, the proximal CX was on the annular or atrial
ide of the CS in the distal CS and crossed to the epicardial
sinus (CS) anatomy in dogs with experimental heart failure (A to C) and
t for explanation. D Anc distal anchor; LAD left anterior descending
Figures 2 and 3.onary
ee tex
s as innd sometimes then ventricular side of the CS over the
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Percutaneous Mitral Annuloplasty October 19, 2004:1652–61istal portion of the CS in the region where the distal
nchor would be positioned (Fig. 4A). The two dogs with
oronary impingement that had assessment of coronary
natomy had this general pattern (Figs. 5 and 6). In three
ogs, the proximal CX was on the atrial or annular side of
he CS in the distal CS and passed on the annular side of
he CS to the ventricular side of the CS in the distal portion
f the CS where the distal anchor would be positioned (Fig.
B). In two dogs, the proximal CX was far down on the
entricular side of the CS and maintained this position
hroughout the distal CS (Fig. 4C).
In one dog, placement of the distal anchor at 90%
esulted in impingement of CX flow (Fig. 5A). Placement
f the device at 85% gave good efficacy with good CX flow
Fig. 5C). The delivery system was uncoupled and within
inutes the dog developed ischemia and CX occlusion was
ocumented. In retrospect, there was impingement on the
X, with the final device placement at 85% compared with
he baseline angiogram (Fig. 5D) that was not appreciated
igure 5. Effect of variable distal anchor placement on coronary flow (A,C)
ed numbers on C indicate the level at which the sections of the AV g
ompared with D. See text for explanation. Abbreviations as in Figure 4.t the time. This dog died and examination of the CX and dS anatomy in the harvested heart revealed that the
roximal CX ran on the atrial side of the CS in the distal CS
nd then crossed over to the epicardial and then ventricular
ide of the CS (Fig. 5B) over the portion of the CS where
he distal anchor was positioned. The proximity of the CX
nd distal CS in this dog may have increased the likelihood
f compression of the CX with tension on the device.
owever, this anatomy was not too dissimilar to that
bserved in two other dogs in which no impingement of CX
ow occurred.
In another dog, placement of the device at 85% did not
mpede coronary flow after deployment of the distal anchor
Fig. 6A, top), but did when tension was applied to cinch
he device and reduce the mitral annulus (Fig. 6A, bottom).
he device was repositioned at 75%, but this position
imited flow with deployment of the distal anchor (Fig. 6C,
eft) and occluded flow with applying tension to cinch up
he annulus (Fig. 6C, right). No device was placed, as less
istal positions afforded unsatisfactory acute efficacy. The
orresponding coronary anatomy (B) in a single dog with experimental HF.
(B) were taken. Black arrow in C indicates luminal irregularity in CXand c
rooveog underwent four weeks’ additional pacing per protocol.
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October 19, 2004:1652–61 Percutaneous Mitral Annuloplastyxamination of CX and CS anatomy after sacrifice revealed
hat the proximal CX ran on the annular side of the CS and
hen spiraled to the atrial, epicardial, and then ventricular
ide of the CS over the portion of the CS where the distal
nchor was positioned.
Thus, 7 of 12 dogs had successful placement to assess
cute and chronic efficacy, 3 of 12 had coronary anatomy
hat precluded efficacious placement of the device without
schemia, and 2 had failure to place the device because of
arly prototype design issues. No CS dissection or perfora-
ion was noted despite placement and repositioning of
ultiple devices in the CS in the final phase with the most
ature prototype.
There was a clear relationship between the degree of
nnular diameter and MR reduction and the position of the
istal anchor, with maximal results achieved with the most
istal placement of the distal anchor. Further, the degree of
nnular diameter and MR reduction were related to the
mount of tension (and thus deformation of the annulus)
laced on the device before deployment of the proximal
nchor. The length of the device is also an important
onsideration, and devices must be appropriately sized to
nsure that the entire device resides in the CS.
CUTE EFFECT ON MR. Figure 7 demonstrates the acute
ffect of the device placement on MR severity as assessed by
our separate indices with grouped data and representative
igure 6. Effect of variable distal anchor placement on coronary flow w
orresponding coronary anatomy (B) in a single dog with experimental Hxamples of each index of MR severity in a single dog at raseline and after device placement. Left ventricular systolic
ressure at the time of baseline and final assessment of MR
ere similar (105  4 mm Hg vs. 106  5 mm Hg, p 
.96). There was a marked reduction in the MR jet area/LA
rea ratio. In one of the seven dogs that had successful
lacement of the device, the baseline PISA could not be
erformed for technical reasons. In two of the six dogs with
aseline PISA measurements, the measurements could not
e obtained after device placement because the residual MR
as minimal and full development of the MR jet by
ontinuous wave Doppler and/or the PISA radius was not
ossible. In the four dogs with paired data, the reduction in
RO and regurgitant volume was significant. By contrast
entriculography, the grade of MR was reduced.
HRONIC EFFECT ON MR. The LV and LA size, ejection
raction, mitral annular dimension, and MR jet area/LA
rea ratio at baseline, after the induction of HF (HF-pre-
evice) and at four weeks (HF-4 weeks) after the device
lacement procedure (with continued rapid pacing) in
urviving dogs who received a device (n  7) and those who
id not (n  3) are shown in Table 2. The pacing protocol
esulted in LV, LA, and mitral annular enlargement; sys-
olic dysfunction; and moderate MR. These changes re-
ained stable to more severe at four weeks in those dogs
hat did not receive a device. In dogs that received a device,
itral annular dimension and MR jet area to LA area were
d without tension in A (top and bottom) and C (left and right) and
e text for explanation. Abbreviations as in Figure 5.ith aneduced compared with the HF-pre-device data.
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Percutaneous Mitral Annuloplasty October 19, 2004:1652–61ISCUSSION
e evaluated potential efficacy and safety of a percutaneous
itral annuloplasty device in a clinically relevant model of
xperimental HF due to rapid ventricular pacing. In the first
tudy we performed, placement of a device in the CS with
imulated deployment reduced mitral annulus diameter and
everity of MR without deleterious hemodynamic effects or
nduction of mitral stenosis. In the second study, which
ore closely approximated the intended clinical scenario,
MA resulted in acute and chronic reduction of mitral
nnular diameter and MR severity. Several important ob-
ervations regarding factors critical for efficacy (optimal
lacement of distal anchor, appropriate anchor size and
evice length, degree of tension needed before deployment)
nd safety (appreciation of the relationship between the CS
nd the circumflex coronary artery and ability to deploy and
ecapture device without CS dissection) were defined.
Functional MR becomes an increasing hemodynamic
urden as LV remodeling progresses in patients with HF,
nd the interaction between the two processes generates a
icious cycle. In a broad spectrum of patients with acute
yocardial infarction or with systolic dysfunction, the
resence of MR is associated with worse outcomes (10,11).
igure 7. Acute effects of percutaneous mitral annuloplasty in dogs in Stu
aseline and post-device are shown in A (*p  0.05 vs. baseline). Represen
nd proximal isovelocity surface area measurements (D) before and after dev
nto pulmonary veins. ERO  effective regurgitant orifice.lthough pharmacologic interventions have been shown to eositively influence LV remodeling, advanced HF fre-
uently develops despite maximal medical therapy. We have
ecently reported that functional MR is common in patients
ith advanced HF referred to a refractory HF clinic (12).
itral annuloplasty is a promising therapy for patients with
dvanced HF and significant functional MR (2). Indeed,
urgical techniques have improved, allowing surgical ap-
roaches to HF even in patients with severe systolic dys-
unction, and there is considerable interest in newer surgical
odalities to prevent the progression of or to reverse LV
emodeling (13). However, 80% of patients with HF are
65 years of age and 50% are 80 years of age. The
revalence of significant renal dysfunction, one or more
revious sternotomies, and other comorbidities in these
lderly patients is high, and many patients with advanced
F and functional MR are not good surgical candidates.
dditional therapeutic options for such patients are needed,
nd the promising results of surgical mitral annuloplasty in
ounger patients with HF suggest that PMA would be an
ffective HF therapy in those patients who are not candi-
ates for surgical approaches.
The present study supports the concept that novel device
herapy to reduce MR severity in HF may be feasible and
Grouped data for all parameters of mitral regurgitation (MR) severity at
examples of contrast ventriculography (B), MR jet area/left atrial area (C)
lacement in a single dog are shown. In B, arrows indicate reflux of contrastdy 2.
tative
ice pffective. It also defines important factors needed for efficacy
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October 19, 2004:1652–61 Percutaneous Mitral Annuloplastynd potential limitations to this approach, most notably the
elationship of the CS and circumflex coronary artery. We had
peculated that if the CX ran between the CS and annulus for
n extended distance, the risk for tension on the device to
ompromise flow would be greatest. However, the two in-
tances of CX compromise did not clearly display this variant.
areful patient selection, device positioning, and sequential
ngiography during device placement will be needed in clinical
tudies in patients with a patent native CX.
The potential for PMA to widen the therapeutic arma-
entarium for advanced HF is very attractive. However, its
otential applicability will need to be assessed on an
ndividual basis, as the presence of active ischemia, an area
f anterior akinesia, or severe tricuspid valve regurgitation
ould make a surgical approach more appealing in those
ho are otherwise surgical candidates. Concomitant severe
ricuspid regurgitation and right HF may also limit clinical
esponse to PMA.
tudy limitations. The degree of MR associated with
apid pacing-induced LV dysfunction in the conscious dog
as not severe. However, under anesthesia in the closed-
hest dog, the severity of MR was more significant and the
evice markedly reduced the severity of MR. Indeed,
limination of milder MR may be more difficult than
eduction of severe MR, as reduction in a less dilated
nnulus may distort leaflet coaptation. In sheep, targeted
oronary ligation has been reported to produce severe MR
14), and such models could be studied as there is concern
hat mitral annuloplasty alone may not provide adequate or
asting reduction of MR in ischemic cardiomyopathy (15).
owever, in sheep the circumflex coronary artery does not
un in the atrioventricular groove, limiting its suitability to
ssess safety issues. There are other factors unique to the
uman HF population that likely cannot be assessed in any
nimal model, and although these studies and others (16,17)
ave provided “proof of principle” and insight into technical
onsiderations, ultimate clinical utility and safety can only
e defined in humans.
onclusions. This new percutaneous mitral annuloplasty
evice significantly reduced mitral annular dimension and the
everity of functional MR associated with severe experimental
F in a species whose CX and CS anatomy are similar to
umans with a left dominant circulation. The need for careful
ssessment of coronary anatomy during implantation is estab-
ished. These data and the promising results obtained with
urgical annuloplasty in advanced human HF associated with
evere functional MR lend support for future clinical studies
hat would define the therapeutic potential and safety of such
evices in human HF.eprint requests and correspondence: Dr. Margaret M. Red-
eld, Mayo Clinic and Foundation, Cardiorenal Laboratory,
uggenheim 9, 200 First Street SW, Rochester, Minnesota
5905. E-mail: redfield.margaret@mayo.edu.
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